Biocon Share Price Rises on UK Approval for Psoriasis Biosimilar and Strong Q4 FY25 Earnings 

 On Monday, May 26, 2025, Biocon share price went up by as much as 1.14%, reaching an intraday high of ₹334.45. At 9:36 AM, the stock was trading at ₹333.05, up 0.73%. In comparison, the BSE Sensex was also in the green, rising 0.79% to 82,363.10.

UK Nod for Biosimilar Drug Boosts Sentiment

Biocon share price rose after Biocon Biologics, a subsidiary of Biocon Ltd, received market approval in the UK for its biosimilar drug Yesintek. This approval came from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). Yesintek is a biosimilar of Ustekinumab, used to treat moderate to severe plaque psoriasis in adults and children over 6 years old. It is also approved for adults with active psoriatic arthritis and Crohn’s disease.

According to Biocon, clinical trials have confirmed that Yesintek is as safe and effective as the original drug. Additionally, the drug has already been approved for marketing in the European Union and the European Economic Area by the European Commission.

Biocon Q4 FY25 Earnings Results Drive Optimism

For the quarter ending March 2025, Biocon reported a sharp 153% rise in net profit to ₹344 crore, compared to ₹136 crore in the same quarter last year. Profit before tax also saw a 53% jump to ₹487 crore. Revenue grew to ₹4,454 crore from ₹3,966 crore a year ago. The company’s EBITDA rose by 16% to ₹1,115 crore, with a stable EBITDA margin of 25%.

This strong performance was supported by growth across Biocon’s key business areas—generics, biologics, and research services.

Fundraising Plan Approved

Biocon’s board has approved a plan to raise up to ₹4,500 crore through options like a qualified institutional placement (QIP), rights issue, or other allowed methods. This move aims to support the company’s growth plans and strengthen its financial position.

Also Read: MTAR Q4FY25 Earnings Result: Revenue and PAT Recorded Significant Growth.  

About Biocon

Biocon is a global biopharmaceutical company focused on offering affordable and innovative treatments for serious health issues like diabetes, cancer, and autoimmune diseases. Operating in more than 120 countries, Biocon is a major player in the biosimilars market, providing cost-effective versions of complex biologics, such as human insulin and insulin glargine.

Conclusion

Biocon’s recent UK approval, strong financial performance, and future capital infusion signal a positive outlook for the company. With global expansion and biosimilar leadership, Biocon continues to strengthen its position in the global biopharma space.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.